StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)

Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%

AbbVie cash

Cash and short-term investments held at the end of each period.

AbbVie's cash was $6.57B at Jun 30, 2026. For fiscal 2025 it was $5.26B, down 5.4% from the year before. Over ten years it grew -4.6% a year on average. The highest annual figure on record is $39.92B in fiscal 2019.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.26B-5.4%
FY2024Dec 31, 2024$5.56B-56.7%
FY2023Dec 31, 2023$12.82B+38.9%
FY2022Dec 31, 2022$9.23B-6.1%
FY2021Dec 31, 2021$9.83B+15.9%
FY2020Dec 31, 2020$8.48B-78.8%
FY2019Dec 31, 2019$39.92B+395.3%
FY2018Dec 31, 2018$8.06B-17.7%
FY2017Dec 31, 2017$9.79B+52.4%
FY2016Dec 31, 2016$6.42B-23.6%
FY2015Dec 31, 2015$8.41B+0.4%
FY2014Dec 31, 2014$8.37B-15.4%
FY2013Dec 31, 2013$9.90B+24.1%
FY2012Dec 31, 2012$7.98B+29440.7%
FY2011Dec 31, 2011$27.00M+170.0%
FY2010Dec 31, 2010$10.00M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.57B+1.6%
Q1 FY2026Mar 31, 2026$9.39B+81.4%
Q4 FY2025Dec 31, 2025$5.26B-5.4%
Q3 FY2025Sep 30, 2025$5.67B-22.2%
Q2 FY2025Jun 30, 2025$6.47B-50.8%
Q1 FY2025Mar 31, 2025$5.18B-71.4%
Q4 FY2024Dec 31, 2024$5.56B-56.7%
Q3 FY2024Sep 30, 2024$7.29B-45.2%
Q2 FY2024Jun 30, 2024$13.16B+50.1%
Q1 FY2024Mar 31, 2024$18.07B+168.8%
Q4 FY2023Dec 31, 2023$12.82B+38.9%
Q3 FY2023Sep 30, 2023$13.29B+11.9%
Q2 FY2023Jun 30, 2023$8.77B-12.0%
Q1 FY2023Mar 31, 2023$6.72B-11.2%
Q4 FY2022Dec 31, 2022$9.23B-6.1%
Q3 FY2022Sep 30, 2022$11.88B-3.0%
Q2 FY2022Jun 30, 2022$9.96B+15.8%
Q1 FY2022Mar 31, 2022$7.57B-22.6%
Q4 FY2021Dec 31, 2021$9.83B+15.9%
Q3 FY2021Sep 30, 2021$12.25B+54.1%
Q2 FY2021Jun 30, 2021$8.60B+42.4%
Q1 FY2021Mar 31, 2021$9.78B-76.2%
Q4 FY2020Dec 31, 2020$8.48B-78.8%
Q3 FY2020Sep 30, 2020$7.95B-25.3%
Q2 FY2020Jun 30, 2020$6.04B+11.5%
Q1 FY2020Mar 31, 2020$41.14B+687.0%
Q4 FY2019Dec 31, 2019$39.92B+395.3%
Q3 FY2019Sep 30, 2019$10.65B+21.2%
Q2 FY2019Jun 30, 2019$5.42B+44.7%
Q1 FY2019Mar 31, 2019$5.23B-44.8%
Q4 FY2018Dec 31, 2018$8.06B-17.7%
Q3 FY2018Sep 30, 2018$8.79B-8.0%
Q2 FY2018Jun 30, 2018$3.74B-48.0%
Q1 FY2018Mar 31, 2018$9.47B+51.6%
Q4 FY2017Dec 31, 2017$9.79B+52.4%
Q3 FY2017Sep 30, 2017$9.55B+20.2%
Q2 FY2017Jun 30, 2017$7.21B–
Q1 FY2017Mar 31, 2017$6.25B–
Q4 FY2016Dec 31, 2016$6.42B–
Q3 FY2016Sep 30, 2016$7.95B–

More AbbVie figures

See a number that looks wrong?